MedWellAI, Inc. (MWAI)

MedWellAI, Inc. operates in a highly competitive environment across the wellness and compounded pharmaceutical sectors, where the broader wellness industry represents a large consumer and clinic economy while compounded pharmaceuticals constitute a smaller but strategically significant segment in the United States ¹. The company's operations compete primarily within the compounded pharmaceutical space, focusing on weight management, hormone therapies, peptides, and personalized care solutions ². The company's e-commerce platform connects in-office buyers with multiple FDA-registered 503B pharmacies, offering GLP-1 weight management therapies, peptides and other compounds ³. The platform provides access to multiple 503B outsourcing facilities, over 100 products, personalized pricing, direct payment deposits, custom domain options, and onboarding support ⁴, enabling procurement agents and resellers to market products to licensed healthcare providers, wellness spas and telemedicine companies in a 100% automated, cost-effective, efficient, compliant and profitable manner without requiring any infrastructure investment ⁵.

Management has not provided specific quantitative revenue, margin, or EPS guidance for the upcoming period. The company anticipates that it will seek to fund its operations through public or private equity or debt financings or other sources, such as potential collaboration agreements ⁶. The amount and timing of future funding requirements will depend on many factors, including the timing and results of ongoing operations, and potential new development and administrative support expenses ⁷. The company's ability to operate profitably is dependent upon, among other things, obtaining additional financing for its operations ⁸. These factors raise substantial doubt about the company's ability to continue as a going concern ⁹.

Management's message to shareholders emphasizes the company's strategic shift from digital asset mining to the health and wellness industry, with a focus on earning commissions through a fully automated e-commerce platform connecting in-office buyers with multiple FDA-registered 503B pharmacies ¹⁷. The company has incurred losses since its organization and is subject to the risks common to start-up, pre-revenue enterprises, including undercapitalization, cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues ¹⁸. Management has identified the need to raise additional capital to continue to operate, complete and successfully operate its business and to fund future operations ¹⁹. The company's strategic priorities include expanding its e-commerce platform, which enables procurement agents and resellers to market products to licensed healthcare providers, wellness spas and telemedicine companies ²⁰, and addressing regulatory hurdles that have impacted its commission revenues ²¹.

Total revenue for the year ended June 30, 2026 was $527,857 ²², compared to $594,768 ²³ for the year ended June 30, 2025. Net loss attributable to MedWellAI, Inc. was $1,589,465 ²⁴ for fiscal 2026, compared to $3,607,145 ²⁵ for fiscal 2025. Net loss per common share attributable to shareholders, basic and diluted, was $(0.24) ²⁶ for fiscal 2026, compared to $(0.49) ²⁷ for fiscal 2025. Loss from operations was $1,236,495 ²⁸ for fiscal 2026, compared to $2,840,574 ²⁹ for fiscal 2025. General and administrative expenses decreased to $1,660,340 ³⁰ in fiscal 2026 from $2,619,322 ³¹ in fiscal 2025. Impairment expense was $38,966 ³² in fiscal 2026, compared to $752,125 ³³ in fiscal 2025. Net cash used in operating activities was $307,030 ³⁴ for fiscal 2026, compared to $935,312 ³⁵ for fiscal 2025. As of June 30, 2026, the company had cash of $86,222 ³⁶ and total current liabilities of $7,959,140 ³⁷, with total stockholders' deficit attributable to shareholders of $7,979,411 ³⁸.

MedWellAI faces material risks specific to its business model and financial condition. The company has incurred losses since inception and has a going-concern qualification from its auditors, with current liabilities exceeding current assets by $7,847,263 ¹⁰ and an accumulated deficit of $90,263,345 ¹¹ as of June 30, 2026. Changes in FDA regulation of compounded pharmaceuticals could adversely affect the supply of GLP-1 medications, as the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List in April 2026 ¹², which could materially limit the supply of products distributed. The company's commission revenues decreased to $437,857 ¹³ in fiscal 2026 from $576,931 ¹⁴ in fiscal 2025 due to regulatory hurdles. The company depends heavily on its chief executive officer, Steve Rubakh, whose departure could harm the business ¹⁵. Additionally, the company's common stock is deemed to be 'penny stock' ¹⁶, which may make it more difficult for investors to sell their shares.